The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 7-8, 2011, Pages 855-861

  Wilckens, Volker ^a   Kannengiesser, Klaus ^a   Hoxhold, Kerstin ^a   Frenkel, Christian ^a   Kucharzik, Torsten ^a   Maaser, Christian ^a  

^a University Teaching Hospital Lueneburg   (Germany)

Author keywords

Immunization; Immunosuppression; Infection; Inflammatory bowel disease

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; CYTOMEGALOVIRUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; INFLIXIMAB; MERCAPTOPURINE; TETANUS TOXOID; YELLOW FEVER VACCINE;

ADOLESCENT; ADULT; ADULTHOOD; AGED; ARTICLE; ATTITUDE TO HEALTH; CHICKENPOX; CHILDHOOD; CONSENSUS; CROHN DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIPHTHERIA; ENTERITIS; FEMALE; GENOTYPE; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VACCINATION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEASLES; MEDICAL RECORD REVIEW; MUMPS; OUTPATIENT; POLIOMYELITIS; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RUBELLA; SEROLOGY; STEROID THERAPY; STREPTOCOCCUS PNEUMONIA; TETANUS; TRAVEL; TUBERCULOSIS; ULCERATIVE COLITIS; YELLOW FEVER;

ADOLESCENT; ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS B; HUMANS; IMMUNIZATION; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PRACTICE GUIDELINES AS TOPIC; TETANUS; VIRUS DISEASES; YOUNG ADULT;

EID: 79960275065     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2011.574734     Document Type: Article

References (23)

1. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010;CD000545.
2. Oussalah A, Danese S, Peyrin-Biroulet L. Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets 2010;11:156-75.
3. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36. (Pubitemid 351451967)
4. Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 2010;24:167-82.
5. Duricova D, Pedersen N, Elkjaer M, Gamborg M, Munkholm P, Jess T. Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies. Inflamm Bowel Dis 2010;16:347-53.
6. Aberra FN, Lichtenstein GR. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis 2005;11:685-95. (Pubitemid 40961083)
7. Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:677-92. (Pubitemid 39276481)
8. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, Munter PD, D'Haens G, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2009;3:47-91.
9. Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Med Clin North Am 2010;94:1-18.
10. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
11. D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol 2010;7: 86-92.
12. Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007; 56:1-54.
13. Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101:1834-40. (Pubitemid 44166594)
14. Danerseau AM, Robinson JL. Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs. World J Pediatr 2008;4:254-8.
15. Lu Y, Bousvaros A. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr 2010;50:562-5.
16. Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009;104:444-53.
17. Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105: 148-54.
18. Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:851-6. (Pubitemid 47031059)
19. Rahier JF, Papay P, Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011;60:456-62.
20. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008;57:549-58. (Pubitemid 351442541)
21. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5. (Pubitemid 39120128)
22. Hou JK, Velayos F, Terrault N, MahadevanU. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010; 16:925-32.
23. Loras C, Gisbert JP, Minguez M, Merino O, Bujanda L, Saro C, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010;59:1340-6.